Acrivon Therapeutics, Inc. Common Stock (ACRV)
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company's platform combines genomics, proteomics, and machine learning to identify targeted therapies and biomarkers, aiming to improve patient outcomes in various oncology indications.
Company News
A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.
Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also fell, dropping, 0.39% to 5,182.36. Check This Out: Robinhood To Rally Around 51%? Here Are 10 Top Analyst Forecasts For Tuesday  Leading and Lagg...
A more selective small-cap index has consistently outperformed the Russell 2000
These two healthcare stocks have crushed the broader markets this year.